‘How long can I go on?’: Cancer patients struggle as drug price caps offer little relief
Source Entity
Anonna Dutt, Anuradha Mascarenhas, Purnima Sah
Despite government-mandated price caps on 1,364 anti-cancer formulations, many patients still face prohibitive costs for specialized immunotherapy. While systemic price reforms aim to save consumers billions, high-cost drugs like pembrolizumab remain financially out of reach for many families.
The Paradox of Progress in Indian Cancer Care
In November 2026, the Indian government implemented a significant regulatory shift by revising the Maximum Retail Prices (MRPs) of 1,364 anti-cancer formulations. Orchestrated by the National Pharmaceutical Pricing Authority (NPPA), this initiative, which caps trade margins on 137 essential cancer drugs, is projected to alleviate the financial burden on patients by approximately ₹3,540 crore annually. This policy move, informed by an expert committee under the Directorate General of Health Services, represents a concerted effort to curb the spiraling costs of life-saving oncology treatments.
The Gap Between Policy and Patient Reality
Despite these broad systemic interventions, the lived experience of patients like 45-year-old Neeta Kumar highlights a persistent crisis. Diagnosed with an aggressive form of breast cancer, Kumar’s treatment plan includes pembrolizumab (Keytruda), an immunotherapy drug that, while effective, carries a staggering cost of at least ₹10 lakh. For many families, the regulatory reduction in prices for standardized formulations does not automatically translate to affordability for newer, high-cost immunotherapy agents that fall outside traditional pricing structures.
Understanding the Cost of Immunotherapy
Immunotherapy drugs like Keytruda are transformative, yet their pricing models often rely on complex patient access programs rather than simple retail price reductions. Under the current manufacturer scheme, a patient must fund the first five infusions out-of-pocket before becoming eligible for 12 additional free infusions. When combined with the baseline costs of chemotherapy, surgical interventions, and supportive care, the financial threshold remains daunting. This creates a scenario where, even with government-led price caps, the absolute cost of advanced care remains prohibitive for the average household.
Structural Challenges in Oncology Economics
The sheer scale of the NPPA’s intervention—covering 85 pharmaceutical companies and over 1,300 formulations—is a monumental administrative achievement. However, the economic reality of oncology care is multifaceted. The transition from traditional chemotherapy to targeted, high-efficacy immunotherapy introduces a new class of financial barriers that current margin-capping policies struggle to fully address. The regulatory focus on trade margins, while helpful for essential medicines, may require further evolution to tackle the high initial acquisition costs of patented biologics.
Future Trends and Policy Implications
Looking ahead, the tension between pharmaceutical innovation and universal healthcare access will likely intensify. As the burden of cancer continues to rise, the government will face increasing pressure to balance the need for affordable access with the necessity of maintaining a pharmaceutical ecosystem that supports the introduction of cutting-edge therapies. Future policy trends will likely involve deeper negotiations with pharmaceutical giants to refine patient access programs, ensuring that the 'free' cycles of medication become accessible earlier in the treatment timeline rather than after significant financial depletion.
Conclusion
In summary, while the government’s recent move to cap anti-cancer drug prices is a vital step toward democratizing healthcare, it is only one piece of a much larger puzzle. The ongoing struggle of patients like Neeta Kumar serves as a poignant reminder that policy efficacy is measured not just by aggregate savings across millions of units, but by the tangible ability of individuals to afford life-saving treatment at the point of care. Achieving true affordability in cancer treatment will necessitate a holistic approach that bridges the gap between regulatory pricing caps and the high-cost reality of modern immunotherapy.